Status:
TERMINATED
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lead Sponsor:
Pfizer
Collaborating Sponsors:
UCB Pharma
Conditions:
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-...
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
April 4 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2014
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT01232556
Start Date
April 4 2011
End Date
March 28 2014
Last Update
January 8 2019
Active Locations (177)
Enter a location and click search to find clinical trials sorted by distance.
1
Disney Family Cancer Center at Providence St Joseph Medical Center
Burbank, California, United States, 91505
2
Providence St Joseph Medical Center
Burbank, California, United States, 91505
3
Hematology-Oncology Medical Group of Fresno Inc
Fresno, California, United States, 93720
4
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
Los Angeles, California, United States, 90095-6981